Cardiff Lexington (OTCQX:CDIX) was approved to trade on the OTCQX Best Market effective April 9, 2026, continuing under symbol CDIX. The upgrade highlights enhanced transparency, governance and a step toward a potential uplisting to a national exchange.
For FY2025 the company reported $11.5M revenue (+39.5% vs 2024), $7.2M gross profit (62.5% margin), $1.1M operating income (9.5% margin) and $29.1M total assets (+21.6%). Management cites working capital constraints as the primary limit on utilization and plans capital formation to scale operations and accelerate AR conversion.
Cardiff Lexington (OTCQB: CDIX) reported full year 2025 results: revenue $11.5M (up 39.5% YoY) and gross profit $7.2M (62.5% margin). Operating income was $1.1M while net loss was $(5.5M) due largely to $6.8M interest expense. The company executed a 1-for-3 reverse split and announced a March 16, 2026 investor webcast.
Management cited higher patient volumes, a shift to higher-value surgical procedures, expanded operations in Florida and Georgia, and talent additions to support growth and a planned uplisting.
Cardiff Lexington (OTCQB: CDIX) will release its fourth quarter and full year 2025 financial and operating results and host a conference call on Monday, March 16, 2026 at 11:00 am ET.
Shareholders can join via dial-in or webcast; a slide deck and an online replay (available through March 30, 2026) will be posted on the company's Investor Relations site.
Cardiff Lexington (OTCQB: CDIX) subsidiary Nova Ortho and Spine expanded its Florida clinical team on February 26, 2026 by hiring two procedurally trained nurse practitioners to support rising patient volume across Orlando and southeastern Florida.
The hires—Catherine Amanda Kelly, MSN, APRN, FNP-BC, and Ashley Logan, APRN-BC—bring combined procedural, neurosurgery, orthopedic surgery and pain management experience intended to improve operational efficiency, safety and patient satisfaction.
Cardiff Lexington Corporation (OTCQB:CDIXD / intends Nasdaq: CDIX) filed a registration statement on Form S-1 on December 15, 2025 for a proposed initial public offering of common stock and announced plans to uplist to Nasdaq Capital Market under the symbol CDIX. The company has engaged R. F. Lafferty & Co., Inc. as sole bookrunning manager to advise on market strategy, capital formation, valuation, investor positioning, and regulatory readiness. The number of shares and price range are not yet determined; the offering is subject to SEC effectiveness, Nasdaq approval, and market conditions.